MMJ PhytoTech’s Israeli division PhytoTech Therapeutics has obtained approvals from Ministry of Health and the Sheba Hospital regulatory body Helsinki, to initiate a Phase II clinical trial of its PTL201 for the treatment of spasticity related symptoms in patients with multiple sclerosis (MS).

Formulated with the firm’s Gelpell-CBD product technology, PTL201 contains a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

THC and CBD are bound to and covered by gelatin matrix beadlets that are packed in gastro-resistant capsules.

The double-blind, randomised, placebo-controlled, parallel-group, single-centre Phase II trial is designed to assess the safety, tolerability and efficacy of oral PTL201 in 70 patients with spasticity related symptoms.

"The double-blind, randomised, placebo-controlled, parallel-group, single-centre Phase II trial is designed to assess the safety, tolerability and efficacy of oral PTL201 in 70 patients with spasticity related symptoms."

MMJ PhytoTech managing director Andreas Gedeon said: “PhytoTech Therapeutics is continuing to implement our ambitious clinical development plan, which is the result of our group’s synergistic global positioning and our focus on science-based product development in the medical cannabis field.

“The current PhaseII clinical trials have the capacity to create significant value for our shareholders, not only on their stand-alone merits in the pharmaceutical development chain, but also by supporting the commercialisation of Satipharm’s Gelpell products, which have been exclusively licensed to Phytotech Therapeutics in the Rx fieldon a royalty-free basis, for the international medical cannabis and dietary supplement markets.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The change in spasticity numerical rate scoring (sNRS scores), walking velocity and clinical global impression improvement (CGI-I) will be measured as the efficacy endpoints during the trial.

The trial will also evaluate other parameters such as the improvement of spasm frequency, sleep disturbance and decrease in pain.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact